Repligen Corporation reports business developments as a global life sciences company focused on bioprocessing technologies and systems used in manufacturing biological drugs. Its updates center on Filtration and Fluid Management, Chromatography, Process Analytics and Proteins, serving biopharmaceutical drug developers, CDMOs and other life science customers.
Recurring announcements include quarterly and annual financial results, financial guidance, organic revenue measures, margin commentary, product and support infrastructure such as Repligen Training & Innovation Centers and OPUS pre-packed chromatography columns, investor conference participation, regional customer support initiatives and board or senior finance governance changes.
Repligen Corporation (NASDAQ:RGEN) reported record Q1 2020 revenue of $76.1 million, a 25% increase year-over-year, driven by 16% organic growth. The company achieved a GAAP gross margin of 58.0%, with GAAP EPS of $0.18. Adjusted EPS rose to $0.32, reflecting strong demand in gene therapy and chromatography sectors. The company maintains its 2020 revenue guidance of $309-$319 million, projecting a 14%-18% overall growth. Optimistic outlook amid COVID-19 efforts, focusing on employee safety while maintaining operational stability.